Pharmacological inhibitors of Mnk for the treatment of cancer

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1050825

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Cancer is a leading cause of death worldwide. In 2010 an estimated 43,000 Australians died from cancer and 114,000 new cases were diagnosed. New treatments are urgently needed. Protein kinases Mnks promote human tumourogenesis, but they are dispensable for normal tissue development. Inhibition of Mnks’ activity therefore presents an excellent strategy for effective and nontoxic cancer therapy. This project aims to develop Mnk inhibitor drug candidates for potential clinic application.

Funded Activity Details

Start Date: 01-01-2013

End Date: 01-01-2016

Funding Scheme: Project Grants

Funding Amount: $505,894.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Chemotherapy

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer therapy | drug discovery | kinase inhibitors | medicinal chemistry | pharmacology | rational drug design | targeted therapy

Related Links